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The hippocampal atrophy consistently found in major depression
may be involved in the pathophysiology of this disease in view of
its critical role in the emotional networks. Evidence is given for the
existence of FGFR1−5-HT1A heteroreceptor complexes which are
involved in neuroplasticity in the hippocampus using the proximity
ligation assay with a partial interface characterization [1]. The
participation of 5-HT1A and FGFR1 homodimers and recruitment
of b-arrestin2 was demonstrated in the FGFR1−5-HT1A heterore-
ceptor complexes upon agonist treatments [2]. Co-activation of the
two protomers also resulted in synergistic increases in extensions
of PC12 cells and neurite densities and protrusions in primary
hippocampal cultures dependent on the receptor interface. We
have also found that acute and a 10 day i.c.v. treatment with
FGF-2 and the 5-HT1A agonist 8-OHDPAT in the Sprague-
Dawley rat can produce synergistic antidepressant effects in the
forced swim test. Thus, this cotreatment may result in more rapid
and stronger antidepressant-like actions than found with SSRIs.
Evidence is also presented for the existence of FGFR1−5-HT1A
heteroreceptor complexes in the mesencephalic raphe 5-HT nerve
cells [3]. The raphe 5-HT1A autoreceptor when being part of
the FGFR1−5-HT1A heteroreceptor complex may therefore have
a beneﬁcial role in depression by assisting in the recovery of
5-HT nerve cell trophism from a state of atrophy including
increased 5-HT synthesis and storage. The ﬁndings indicate that
neurotrophic and antidepressant effects of 5-HT may, in part, be
mediated by activation of the 5-HT1A receptor protomer in the
hippocampal FGFR1−5-HT1A receptor complex enhancing the
FGFR1 signaling.
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In 1909 the noncatecholic biogenic amines phenylethylamine and
tyramine were shown to produce robust cardiovascular effects
in mammals. With the discovery of synephrine, octopamine and
tryptamine throughout the animal kingdom the trace amines as
they came to be known enjoyed widespread attention from physi-
ologists and neuroscientists for more than 50 years until receptors
for their relatives dopamine, norepinephrine and serotonin were
cloned in the mid-1980s. During the 15 years that followed
no trace amine receptor was discovered and the ﬁeld slid into
relative obscurity. Then, in 2001 two groups using related but
different methodological approaches reported discovery of an
orphan Galphas protein-coupled receptor [1] that is activated by
trace amines and is now referred to as trace amine-associated
receptor 1 (TAAR1) [2]. Progress toward understanding the bi-
ology of TAAR1 in health and disease was initially slow due
to a complete lack of animal models, antibodies and selective
pharmacologic tools. However, with the recent availability of
mouse lines lacking taar1−/− as well as the TAAR1-selective
antagonist EPPTB [3] it has become possible to explore the
role(s) of TAAR1 in vivo. Using a line of TAAR1-deﬁcient mice
generated at UC Davis and EPPTB made in-house we have taken
a translational approach to exploring the contribution of TAAR1-
mediated signaling to the physiological and behavioral effects
of cocaine, methamphetamine and bupropion. Based on our re-
sults we conclude methamphetamine-activated TAAR1-mediated
signaling accounts for ~70% of the drug’s stimulatory effect on
locomotion in mice with the remaining 30% due to its interference
with dopamine transport.
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G protein-coupled Trace Amine-Associated Receptor 1 (TAAR1)
is emerging as a promising new drug target for psychiatric disor-
ders. Recent progress in identifying selective ligands for TAAR1
led to the possibility of evaluation of the functional consequences
